RecruitingPhase 1Phase 2NCT03255408

Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia

Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia


Sponsor

University of Calgary

Enrollment

12 participants

Start Date

Jan 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria5

  • Healthy adults
  • - 45 years of age
  • Living in Calgary for the past one year
  • Have no medical condition or should not be taking any blood pressure medications.
  • The participant should not be lactose intolerant

Exclusion Criteria5

  • Cerebrovascular, cardio-respiratory, renal and metabolic diseases
  • Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease
  • Pregnancy, obese and sleep-disordered breathing
  • Drug allergies to non-steroidal anti-inflammatories
  • Currently smoking

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDrug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep

The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure

DRUGDrug Lowering CBF and Intermittent Hypoxia Sleep

The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure

DRUGPlacebo and Normoxia Sleep

The study participants will take Placebo and sleep under Normoxia Exposure

DRUGPlacebo and Intermittent Hypoxia Sleep

The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure


Locations(1)

University of Calgary

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03255408


Related Trials